Trial · NCT06505395
A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
NCT06505395, Phase 2, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET). Trials, record NCT06505395. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06505395
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
- NCT number
- NCT06505395
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 90 participants, estimated
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Conditions
- Gastrointestinal Neuroendocrine Pancreatic Tumor
- Interventions
- SYHX2008 injection, Sandostatin LAR@
- First posted
- 2024-07-17
- Last updated
- 2024-08-26
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) as assessed by a Blinded Independent Review Committee (BIRC) | Up to 1 years following the last patient enrolled | PFS is defined as time from the date of randomization to the date of the first documented disease progression as per RECIST 1.1 or death due to any cause (whichever occurs first) |
| Secondary | Overall survival (OS) | Up to 1 years following the last patient enrolled | The time from the date of randomization to the date of death due to any cause |
| Secondary | PFS as assessed by local Investigators | Up to 1 years following the last patient enrolled | PFS as assessed by local Investigators |
| Secondary | Overall response rate(ORR) | Up to 1 years following the last patient enrolled | The proportion of patients with best overall response of complete response (CR) or partial response (PR), according to RECIST 1.1 |
| Secondary | Disease control rate (DCR) | Up to 1 years following the last patient enrolled | The proportion of patients with a best overall response of CR, PR or stable disease (SD), according to RECIST 1.1 |
| Secondary | Duration of response (DOR) | Up to 1 years following the last patient enrolled | The time from the date of the first documented response of CR or PR to the date of the first documented progression or death due to underlying cancer, according to RECIST 1.1 |
| Secondary | Time to Tomor Progression(TTP) | Up to 1 years following the last patient enrolled | TTP is defined as time from the date of randomization to the date of the first documented disease progression as per RECIST 1.1 |
| Secondary | Control of cancer-like symptoms (diarrhea and/or flushing) | Up to 1 years following the last patient enrolled | Assess the total occurrences of diarrhea and/or flushing ( cancer-like symptoms): Evaluate every 8 weeks (±3 days) for the first 12 months following the initial dosage, then every 12 weeks (±7 days). This assessment is based on the total instances of diarrhea and/or flushing episodes within the 7 days preceding the assessment visit. |
| Secondary | Incidence of treatment-emergent adverse events | Up to 1 years following the last patient enrolled | Incidence of treatment-emergent adverse events |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06505395
GET https://conductscience.org/api/trials/v1/NCT06505395/registered